Similar articles

• Effects of nateglinide and glibenclamide on postprandial lipid and glucose metabolism in type 2 diabetes.

  Vakkilainen J, Mero N, Schweizer A, Foley JE, Taskinen MR. Vakkilainen J, et al. Diabetes Metab Res Rev. 2002 Nov-Dec;18(6):484-90. doi: 10.1002/dmrr.324. Diabetes Metab Res Rev. 2002. PMID: 12469362 Clinical Trial.
• Nateglinide--current and future role in the treatment of patients with type 2 diabetes mellitus.

  Campbell IW. Campbell IW. Int J Clin Pract. 2005 Oct;59(10):1218-28. doi: 10.1111/j.1368-5031.2005.00669.x. Int J Clin Pract. 2005. PMID: 16178991 Review.
• Additive hypoglycaemic effect of nateglinide and exogenous glucagon-like peptide-1 in type 2 diabetes.

  Bell PM, Cuthbertson J, Patterson S, O'Harte FP. Bell PM, et al. Diabetes Res Clin Pract. 2011 Mar;91(3):e68-70. doi: 10.1016/j.diabres.2010.11.033. Epub 2010 Dec 30. Diabetes Res Clin Pract. 2011. PMID: 21194775 Clinical Trial.
• Acute nateglinide administration in subjects with type 2 diabetes: effects on postprandial metabolism, coagulation, and fibrinolysis.

  Tentolouris N, Boutati E, Karambakalis N, Perrea D, Tselepis AD, Tsoukala C, Kyriaki D, Lourida E, Anastasopoulou I, Karafoullidou A, Raptis SA, Katsilambros N. Tentolouris N, et al. Nutr Metab Cardiovasc Dis. 2005 Feb;15(1):6-12. doi: 10.1016/j.numecd.2004.06.002. Nutr Metab Cardiovasc Dis. 2005. PMID: 15871845 Clinical Trial.
• Quo vadis nateglinide? Ten-year perspective.

  Grunberger G. Grunberger G. Expert Opin Pharmacother. 2011 Sep;12(13):2097-106. doi: 10.1517/14656566.2011.600305. Epub 2011 Jul 30. Expert Opin Pharmacother. 2011. PMID: 21801074 Review.